Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)	Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, tuberculosis	Not yet recruiting	Phase 3	2020-07-24		NCT04485156

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chonnam National University Hospital	54
International Tuberculosis Research Center	2
Korean Center for Disease Control and Prevention	3
Korean Institute of Tuberculosis	2
National Medical Center, Seoul	3
Pusan National University Hospital	19
Pusan National University Yangsan Hospital	43
Seoul National University Bundang Hospital	114
Seoul National University Hospital	277
Severance Hospital	45
SMG-SNU Boramae Medical Center	26

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine	Seoul	South Korea	1